Articles
Notes on immunoassays and drug monitoring
Background on ELISA methods, therapeutic drug monitoring, anti-drug antibodies, biosimilars, and assay validation.
35 articles
One Platform, All Analytes: Why Microvolume Whole Blood Is Reframing Immunosuppressant TDM
Conventional immunosuppressant TDM splits calcineurin inhibitors and mycophenolic acid across two matrices, two workflows, and two pretreatment pipelines. A 2026 integrated analytical framework published in Bioanalysis, supported by recent LC-MS/MS validation studies using 2.8 µL fingerstick whole blood, challenges that assumption directly. This article reviews the analytical evidence, the hematocrit correction requirement, and what the framework means for assay scientists building fit-for-purpose microvolume methods.
When ADA Titer Is Not Enough: Rethinking the Gate to Neutralizing Antibody Testing
A series of papers published in Bioanalysis throughout 2026 argues that titer-gated neutralizing antibody testing can miss clinically relevant neutralization while generating incidence numbers that mislead development teams. The papers converge on signal-to-noise ratio from the screening tier as a continuous, biologically richer alternative to discretized titer scores, and call for NAb assay sensitivity to be matched to molecule-specific clinical endpoints rather than population-average tier thresholds.
Multiplex Luminex Assay Enables Simultaneous Domain-Specific ADA Detection for Multidomain Biotherapeutics
Standard bridging immunogenicity assays cannot distinguish which domain of a multidomain biotherapeutic is driving an anti-drug antibody response. A Luminex bead-based multiplex approach published in Bioanalysis in November 2026 addresses this gap by enabling simultaneous, domain-resolved ADA detection within a single assay well, with sub-100 ng/mL sensitivity and no prozone effects up to 20,000 ng/mL. This article reviews the method, its validation considerations, and what it means for scientists building immunogenicity programs for bispecific antibodies and other multidomain drugs.
Pembrolizumab Biosimilars Are Entering Clinical Review: What the PK-Only Pathway Means for Immunogenicity Assay Scientists
The FDA accepted the first publicly announced pembrolizumab biosimilar BLA for review in October 2026, using a pharmacokinetic-only pivotal strategy that skips a comparative Phase 3 efficacy trial. For immunogenicity assay scientists, this regulatory pivot reframes how ADA comparability must be designed, validated, and interpreted in a drug class with low but clinically consequential reference product immunogenicity.